Purnanand Sarma, Immunome CEO
January 6, 2023 10:59 AM ESTUpdated 12:49 PM
Deals

Bet­ting on cell mem­o­ry, Ab­b­Vie pays Im­munome $30M up­front to fur­ther an­ti­body re­search

Katherine Lewin

News Reporter

Ab­b­Vie has tapped Im­munome’s dis­cov­ery plat­form in a heav­i­ly back­end­ed part­ner­ship and op­tion agree­ment in a bid to dis­cov­er 10 an­ti­body-tar­get pairs from three as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times